Skip to main content
. 2014 Nov 13;55(11):7387–7397. doi: 10.1167/iovs.14-14651

Figure 10.

Figure 10

Comparison of decrease in IOP caused by supraciliary delivery versus topical delivery of brimonidine. (a) Data from Figures 3a and 9 are graphed together to show the dose-response relationship after supraciliary delivery and to facilitate comparison with topical delivery in the treated eyes. (b) Pharmacodynamic area under the curve (AUCPD) after supraciliary delivery in treated and contralateral eyes and in comparison with topical delivery. AUCPD was calculated using Equation 1.